NasdaqGS:ALKSBiotechs
The Bull Case For Alkermes (ALKS) Could Change Following Vibrance-12 Data And Russell 2000 Inclusion
In late June 2026, Alkermes plc reported positive Phase 2 Vibrance-12 results for its oral orexin 2 receptor agonist alixorexton in narcolepsy type 2, while also being added to the Russell 2000 Dynamic Index.
The combination of clinically meaningful wakefulness and safety data with inclusion in a major benchmark index strengthens Alkermes’ profile in sleep medicine and broadens its visibility with institutional investors.
Next, we’ll examine how the Vibrance-12 alixorexton data could reshape...